Exelixis announced robust earnings for Q1 2025 with significant revenue growth and enhanced earnings per share, alongside revised upward earnings guidance for the fiscal year. These announcements coincided with positive product developments, including FDA approval of CABOMETYX® for additional tumor treatments and phase 1 initiation of the bispecific antibody XB628. During this period, the company's share price advanced 26.49%, a strong performance amidst a relatively stable broader market. While Exelixis's upward movement outperformed the market, it's noteworthy that broader economic and corporate developments added weight to this positive trajectory, despite existing market pressures like increased Treasury yields.

Exelixis has 1 weakness we think you should know about.NasdaqGS:EXEL Earnings Per Share Growth as at May 2025

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Exelixis's recent announcements, specifically the Q1 2025 robust earnings and updated fiscal year guidance, align well with their ongoing developments in oncology treatments. The FDA approval of CABOMETYX for additional tumor treatments and initiation of bispecific antibody XB628 further bolster growth prospects. These developments are expected to positively impact revenue growth and improve earnings forecasts, particularly as the cabozantinib and zanzalintinib pipelines progress through their respective clinical phases. Over the longer term, Exelixis achieved a total return of 150.62% in the past three years, showcasing strong performance in addition to the recent 26.49% share price increase post-announcement.

In comparison to the market, over the past year, Exelixis outperformed both the US Biotechs industry, which returned significantly less, and the general US market, which registered an 11.1% return. This impressive outperformance underscores the company's ability to capitalize on its development pipeline and strategic focus in oncology. The share price currently trading at US$36.86 remains close to the analyst consensus price target of US$38.05, indicating that Exelixis may be fairly priced in the view of the market. Investors may observe the company’s responsiveness to emerging opportunities and potential headwinds as it seeks to maintain its growth trajectory in a highly competitive sector.

Assess Exelixis' previous results with our detailed historical performance reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NasdaqGS:EXEL.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments